Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver

Trial Profile

Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2018

At a glance

  • Drugs Besifovir (Primary) ; Levocarnitine (Primary) ; Tenofovir alafenamide
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Ildong Pharmaceutical
  • Most Recent Events

    • 21 Aug 2018 Planned initiation date changed from 23 Jul 2018 to 23 Sep 2018.
    • 31 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top